Oncolytic viruses and methods for treating neoplastic disorders

US9370550B2 · kind B2 · utility

Assignee

• The Governors of the University of Alberta · CA

Inventors

• David H. Evans · Cambridge, US
• Don B. Gammon · Worcester, US

Key dates

• Filing date: Jan 28, 2014
• Grant date: Jun 21, 2016
• Expiry date: Mar 3, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2710/24162
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The disclosure provides mutant ribonucleotide reductase strains of poxviruses including for example vaccinia viruses. The disclosure also provides methods and for the use of these mutant ribonucleotide reductase strains of vaccinia viruses in oncolytic virotherapy. Also provided in the disclosure are vector constructs for generating mutant ribonucleotide reductase strains of poxviruses including for example vaccinia viruses. The disclosure also provides poxviruses comprising a functionally inactivated R2 gene.